Trial Profile
A Randomized, Double-blind, Placebo-controlled Study of Everolimus in the Treatment of Patients With Subependymal Giant Cell Astrocytomas (SEGA) Associated With Tuberous Sclerosis Complex (TSC)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Everolimus (Primary)
- Indications Astrocytoma; Tuberous sclerosis
- Focus Registrational; Therapeutic Use
- Acronyms EXIST-1
- Sponsors Novartis
- 19 Jul 2018 Results assessing the effect of everolimus on renal function in patients with tuberous sclerosis complex from EXIST-1 and EXIST-2 studies, published in the Nephrology Dialysis Transplantation.
- 21 Apr 2016 Results (n=119) of pooled analysis of 3 studies (NCT00411619, NCT00789828 and NCT00790400) analysing endocrine and menstrual cycle-related events in females presented at the 68th Annual Meeting of the American Academy of Neurology
- 08 Mar 2016 Long-term results from this trial and from EXIST-2 trial presented at the 74th Annual Meeting of the American Academy of Dermatology